CDSCO Moves Clinical Trial Site Addition, PI Change Applications to Online Platform
New Delhi: The Central Drugs Standard Control Organization (CDSCO), under the Directorate General of Health Services, has announced a streamlined procedure for submitting applications related to clinical trials by introducing an online system through the SUGAM Portal.
In a recent notice, CDSCO has mandated that applications for adding clinical trial sites and changing principal investigators must now be submitted through the SUGAM portal, an online platform designed to simplify and expedite regulatory processes.
This new system applies to various types of clinical trials, including global clinical trials, trials for new drugs, subsequent new drugs, investigational new drugs, fixed-dose combinations, and bioavailability & bioequivalence studies. The shift to an online system underscores CDSCO’s commitment to improving efficiency and transparency in clinical trial management.
"The submission of applications for addition of Clinical Trial Site and change of Principal Investigator are functional on online system of SUGAM Portal (www.cdscoonline.gov.in) for Global Clinical Trials„ Clinical trials of New Drugs, Subsequent New Drugs, investigational New Drugs, Fixed Dose Combinations and Bioavailability & Bioequivalence studies. Applicants seeking for approval of Clinical Trial Site Addition and change of Principal Investigator applications may apply through the online portal," the notice read.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.